Bullish & Foolish
Full VIVS fundamentals All 466 on the Survival Watch

VIVSVivoSim Labs, Inc.

Is VivoSim Labs struggling financially?

Yes, by its own account. VivoSim Labs told the SEC on 14 Jul 2026, in Form 10-K, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed Jul 2026

15/100

Critical

Cries for help

  • Needs to raise money

    As the Company continues its operations and is focusing its efforts on services, research, and development, the Company will need to raise additional capital to implement this business plan.

    Form 10-Q, filed 11 Feb 2026. Read it on SEC.gov

Signs of a way out

Nothing in the filings we have read names a way out.

Sector
Biotech/Pharma
Market cap
$4.2M
Source filing
10-K 14 Jul 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$1.7M

÷

Cash burned over the last 12 months

$10.8M

What VivoSim Labs told the SEC

…may affect the prices that can be charged if drug candidates are approved for commercialization. Management has performed an analysis and concluded that substantial doubt exists about our ability to continue as a going concern. Separately, our independent registered public accounting firm has included in its opinion for the year ended March 31, 2026 an explanatory paragraph expressing substantial doubt in…

VivoSim Labs, Inc., Form 10-K, filed 14 Jul 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 109.3% share-count increase The company issued stock. Each share now owns 52.2% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 43% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt